A treatment strategy which enhances anti-tumor effects by the OX40 agonist may involve risks of activating tumor cell growth in MF/SS whereas blocking OX40-OX40L would inhibit tumor growth. The gene discussed is TNFRSF4; the disease is neoplasm.